» Articles » PMID: 22752992

Differences in Human Papillomavirus Type Distribution in High-grade Cervical Intraepithelial Neoplasia and Invasive Cervical Cancer in Europe

Abstract

Knowledge of differences in human papillomavirus (HPV)-type prevalence between high-grade cervical intraepithelial neoplasia (HG-CIN) and invasive cervical cancer (ICC) is crucial for understanding the natural history of HPV-infected cervical lesions and the potential impact of HPV vaccination on cervical cancer prevention. More than 6,000 women diagnosed with HG-CIN or ICC from 17 European countries were enrolled in two parallel cross-sectional studies (108288/108290). Centralised histopathology review and standardised HPV-DNA typing were applied to formalin-fixed paraffin-embedded cervical specimens dated 2001-2008. The pooled prevalence of individual HPV types was estimated using meta-analytic methods. A total of 3,103 women were diagnosed with HG-CIN and a total of 3,162 with ICC (median ages: 34 and 49 years, respectively), of which 98.5 and 91.8% were HPV-positive, respectively. The most common HPV types in women with HG-CIN were HPV16/33/31 (59.9/10.5/9.0%) and in ICC were HPV16/18/45 (63.3/15.2/5.3%). In squamous cell carcinomas, HPV16/18/33 were most frequent (66.2/10.8/5.3%), and in adenocarcinomas, HPV16/18/45 (54.2/40.4/8.3%). The prevalence of HPV16/18/45 was 1.1/3.5/2.5 times higher in ICC than in HG-CIN. The difference in age at diagnosis between CIN3 and squamous cervical cancer for HPV18 (9 years) was significantly less compared to HPV31/33/'other' (23/20/17 years), and for HPV45 (1 year) than HPV16/31/33/'other' (15/23/20/17 years). In Europe, HPV16 predominates in both HG-CIN and ICC, whereas HPV18/45 are associated with a low median age of ICC. HPV18/45 are more frequent in ICC than HG-CIN and associated with a high median age of HG-CIN, with a narrow age interval between HG-CIN and ICC detection. These findings support the need for primary prevention of HPV16/18/45-related cervical lesions.

Citing Articles

Spatiotemporal dynamics and prevention strategies of cervical cancer incidence in Addis Ababa, Ethiopia: an ecological study.

Shimels T, Kantelhardt E, Assefa M, Gedif Fenta T BMJ Open. 2025; 15(1):e089521.

PMID: 39832988 PMC: 11751793. DOI: 10.1136/bmjopen-2024-089521.


Head-to-head comparison of 7 high-sensitive human papillomavirus nucleic acid detection technologies with the SPF10 LiPA-25 system.

Yin J, Cheng S, Liu D, Tian Y, Hu F, Zhang Z J Natl Cancer Cent. 2024; 2(3):148-154.

PMID: 39036447 PMC: 11256530. DOI: 10.1016/j.jncc.2022.06.003.


Do Concurrent Multiple Infections with High-Risk HPVs Carry a More Malignant Potential than a Single Infection in the Uterine Cervix?.

Lee J, Lee H J Clin Med. 2023; 12(19).

PMID: 37834799 PMC: 10573320. DOI: 10.3390/jcm12196155.


HPV prevalence and genotype distribution in 2,306 patients with cervical squamous cell carcinoma in central and eastern China.

Han C, Huang W, Ye M, Zou R, Lan J, Chen J Front Public Health. 2023; 11:1225652.

PMID: 37701907 PMC: 10493278. DOI: 10.3389/fpubh.2023.1225652.


Detection of 14 High-risk Human Papillomavirus (HPV) Genotypes Within the Italian Cervical Cancer Screening.

Cenci M, Rossi F, Pisani T In Vivo. 2023; 37(5):2161-2165.

PMID: 37652482 PMC: 10500497. DOI: 10.21873/invivo.13314.